WEKO3
アイテム
{"_buckets": {"deposit": "e010029b-3ea3-4899-a282-345506c2d274"}, "_deposit": {"id": "8013", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "8013"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00008013", "sets": ["883"]}, "author_link": ["21995", "21996", "21997", "21998", "21999", "22000", "22001", "22002", "22003"], "item_1628147817048": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_6_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-04", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "796", "bibliographicPageStart": "794", "bibliographicVolumeNumber": "46", "bibliographic_titles": [{"bibliographic_title": "TRANSPLANTATION PROCEEDINGS"}]}]}, "item_6_description_20": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Introduction. Once-daily extended-release tacrolimus (Tac-OD) is expected to reduce non-adherence in recipients after liver transplantation (LT). The aim of this study was to determine the optimal initial dose of orally administered Tac-OD after intravenous tacrolimus (Tac-IV) therapy after LT. Patients and Methods. This prospective study included 10 adult recipients who had undergone LT at our institute. The recipients were prescribed tacrolimus by continuous intravenous administration with a steroid as initial immunosuppression therapy. Tacrolimus was converted from intravenous administration to once-daily oral intake when gastrointestinal function returned. We evaluated tacrolimus concentrations in blood 9 times a day and area under the blood concentration time curve (AUC) during conversion. The optimal initial dose of Tac-OD was determined based on simple regression analysis between the oral dose of Tac-OD and the total dose of Tac-IV during a 24-hour period. Results. The AUC before and after conversion showed no differences. We found that the optimal initial dose of Tac-OD was 8 times the dose of Tac-IV. There was a relationship between the AUC and the trough level. No recipients experienced acute rejection or adverse effects such as renal failure, neurotoxicity, or cardiac failure during conversion. Conclusions. We successfully converted continuous Tac-IV to oral intake of Tac-OD by adjusting the dose using trough levels without acute rejection or adverse effects. The AUC of Tac-OD correlated with the trough level. The optimal initial dose ratio of Tac-OD after Tac-IV was 8:1.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "資源タイプ(コンテンツの種類)", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "TRANSPLANTATION PROCEEDINGS. 46(3):794-796 (2014)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "信州大学研究者総覧へのリンク", "attribute_value_mlt": [{"subitem_link_text": "Mita, A", "subitem_link_url": "https://soar-rd.shinshu-u.ac.jp/profile/ja.gFTNHVkh.html"}, {"subitem_link_text": "Ikegami, T", "subitem_link_url": "https://soar-rd.shinshu-u.ac.jp/profile/ja.WpcCHFkh.html"}, {"subitem_link_text": "Ohno, Y", "subitem_link_url": "https://soar-rd.shinshu-u.ac.jp/profile/ja.jUSVbaym.html"}, {"subitem_link_text": "Nakazawa, Y", "subitem_link_url": "https://soar-rd.shinshu-u.ac.jp/profile/ja.uFyCuUkh.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000335294900035"}]}, "item_6_publisher_4": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "ELSEVIER SCIENCE INC"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "24767351"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://pubmed.ncbi.nlm.nih.gov/24767351", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1016/j.transproceed.2014.01.006"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1016/j.transproceed.2014.01.006", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright© 2014 Elsevier Inc."}]}, "item_6_select_64": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0041-1345", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0041-1345", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_40": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00868957", "subitem_source_identifier_type": "NCID"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "Introduction. Once-daily extended-release tacrolimus (Tac-OD) is expected to reduce non-adherence in recipients after liver transplantation (LT). The aim of this study was to determine the optimal initial dose of orally administered Tac-OD after intravenous tacrolimus (Tac-IV) therapy after LT. Patients and Methods. This prospective study included 10 adult recipients who had undergone LT at our institute. The recipients were prescribed tacrolimus by continuous intravenous administration with a steroid as initial immunosuppression therapy. Tacrolimus was converted from intravenous administration to once-daily oral intake when gastrointestinal function returned. We evaluated tacrolimus concentrations in blood 9 times a day and area under the blood concentration time curve (AUC) during conversion. The optimal initial dose of Tac-OD was determined based on simple regression analysis between the oral dose of Tac-OD and the total dose of Tac-IV during a 24-hour period. Results. The AUC before and after conversion showed no differences. We found that the optimal initial dose of Tac-OD was 8 times the dose of Tac-IV. There was a relationship between the AUC and the trough level. No recipients experienced acute rejection or adverse effects such as renal failure, neurotoxicity, or cardiac failure during conversion. Conclusions. We successfully converted continuous Tac-IV to oral intake of Tac-OD by adjusting the dose using trough levels without acute rejection or adverse effects. The AUC of Tac-OD correlated with the trough level. The optimal initial dose ratio of Tac-OD after Tac-IV was 8:1."}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Mita, A", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "21995", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikegami, T", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "21996", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masuda, Y", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "21997", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsuyama, Y", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "21998", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohno, Y", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "21999", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Urata, K", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "22000", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakazawa, Y", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "22001", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kobayashi, A", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "22002", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyagawa, S", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "22003", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-25"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Optimal_initial_dose_orally_administered.pdf", "filesize": [{"value": "652.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 652800.0, "url": {"label": "Optimal_initial_dose_orally_administered.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/8013/files/Optimal_initial_dose_orally_administered.pdf"}, "version_id": "61c5a1ae-ad26-4305-af8a-75b846867d9c"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Optimal Initial Dose of Orally Administered Once-daily Extended-release Tacrolimus Following Intravenous Tacrolimus Therapy After Liver Transplantation", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Optimal Initial Dose of Orally Administered Once-daily Extended-release Tacrolimus Following Intravenous Tacrolimus Therapy After Liver Transplantation", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["883"], "permalink_uri": "http://hdl.handle.net/10091/17694", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2014-07-09"}, "publish_date": "2014-07-09", "publish_status": "0", "recid": "8013", "relation": {}, "relation_version_is_last": true, "title": ["Optimal Initial Dose of Orally Administered Once-daily Extended-release Tacrolimus Following Intravenous Tacrolimus Therapy After Liver Transplantation"], "weko_shared_id": -1}
Optimal Initial Dose of Orally Administered Once-daily Extended-release Tacrolimus Following Intravenous Tacrolimus Therapy After Liver Transplantation
http://hdl.handle.net/10091/17694
http://hdl.handle.net/10091/17694029cca71-07b0-4f1a-9f77-670f70467247
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2014-07-09 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Optimal Initial Dose of Orally Administered Once-daily Extended-release Tacrolimus Following Intravenous Tacrolimus Therapy After Liver Transplantation | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
著者 |
Mita, A
× Mita, A× Ikegami, T× Masuda, Y× Katsuyama, Y× Ohno, Y× Urata, K× Nakazawa, Y× Kobayashi, A× Miyagawa, S |
|||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Mita, A | |||||
URL | https://soar-rd.shinshu-u.ac.jp/profile/ja.gFTNHVkh.html | |||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Ikegami, T | |||||
URL | https://soar-rd.shinshu-u.ac.jp/profile/ja.WpcCHFkh.html | |||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Ohno, Y | |||||
URL | https://soar-rd.shinshu-u.ac.jp/profile/ja.jUSVbaym.html | |||||
信州大学研究者総覧へのリンク | ||||||
氏名 | Nakazawa, Y | |||||
URL | https://soar-rd.shinshu-u.ac.jp/profile/ja.uFyCuUkh.html | |||||
出版者 | ||||||
出版者 | ELSEVIER SCIENCE INC | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | TRANSPLANTATION PROCEEDINGS. 46(3):794-796 (2014) | |||||
書誌情報 |
TRANSPLANTATION PROCEEDINGS 巻 46, 号 3, p. 794-796, 発行日 2014-04 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Introduction. Once-daily extended-release tacrolimus (Tac-OD) is expected to reduce non-adherence in recipients after liver transplantation (LT). The aim of this study was to determine the optimal initial dose of orally administered Tac-OD after intravenous tacrolimus (Tac-IV) therapy after LT. Patients and Methods. This prospective study included 10 adult recipients who had undergone LT at our institute. The recipients were prescribed tacrolimus by continuous intravenous administration with a steroid as initial immunosuppression therapy. Tacrolimus was converted from intravenous administration to once-daily oral intake when gastrointestinal function returned. We evaluated tacrolimus concentrations in blood 9 times a day and area under the blood concentration time curve (AUC) during conversion. The optimal initial dose of Tac-OD was determined based on simple regression analysis between the oral dose of Tac-OD and the total dose of Tac-IV during a 24-hour period. Results. The AUC before and after conversion showed no differences. We found that the optimal initial dose of Tac-OD was 8 times the dose of Tac-IV. There was a relationship between the AUC and the trough level. No recipients experienced acute rejection or adverse effects such as renal failure, neurotoxicity, or cardiac failure during conversion. Conclusions. We successfully converted continuous Tac-IV to oral intake of Tac-OD by adjusting the dose using trough levels without acute rejection or adverse effects. The AUC of Tac-OD correlated with the trough level. The optimal initial dose ratio of Tac-OD after Tac-IV was 8:1. | |||||
資源タイプ(コンテンツの種類) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Article | |||||
ISSN | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 0041-1345 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00868957 | |||||
PubMed | ||||||
識別子タイプ | PMID | |||||
関連識別子 | https://pubmed.ncbi.nlm.nih.gov/24767351 | |||||
関連名称 | 24767351 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1016/j.transproceed.2014.01.006 | |||||
関連名称 | 10.1016/j.transproceed.2014.01.006 | |||||
権利 | ||||||
権利情報 | Copyright© 2014 Elsevier Inc. | |||||
出版タイプ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
WoS | ||||||
表示名 | Web of Science | |||||
URL | http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000335294900035 |